Abstract 154P
Background
The variants of urothelial carcinoma such as micropapillary (MP), plasmacytoid (PC), and lipid cell (LC) carry a very poor prognosis. High progression speed and resistance to chemotherapy are considered to be part of the reasons for poor prognosis. Accordingly, early diagnosis and early treatment are important to improve prognosis. In this study, we elucidated the cytological diagnostic criteria of these variants, and also investigated whether preoperative urine cytology could diagnose these variants and the possible association between cytological predictability and pathological features.
Methods
Between April 2015 and March 2020, 45 patients were histologically diagnosed as MP, PC, and LP by TURBT in our institution. The experienced cytologists (YW) in our hospital re-evaluated the preoperative urine cytology in these cases to determine whether or not the prediction of the variant histology is possible. The following findings were used as criteria, small papillary cell clumps with strong binding in MP, circular atypical cells similar to plasma cells in PC, and atypical cells similar to lipoblasts with empty cells in LC. Additionally, we analyzed whether histopathological findings such as muscle invasion, tumor size, tumor necrosis, lymphovascular invasion (LVI), CIS, affect the prediction of the variants.
Results
Of 45 cases, MP, PC and LC were 18 (40%), 13 (29%) and 14 (31%) patients, respectively. 3 cases of MP (17%), 5 of PC (38%) and 2 of LC (14%) could be predicted by re-evaluating preoperative urine cytology. In addition, positive preoperative urine cytology (class 4 or higher) was found in 14 cases in MP (78%), 8 cases in PC (62%), and 11 cases in LC (79%), with estimated probabilities of 21%, 62%, and 18%, respectively. Pathological features were not different between the predictable and unpredictable cases: muscle invasion, 90% vs 74% (P = 0.26); median tumor size, 31 mm vs 38 mm (P = 0.37); tumor necrosis, 20% vs 28% (P = 0.64); LVI, 60% vs 45% (P = 0.42); CIS, 40% vs 34% (P = 0.74), respectively.
Conclusions
Although in some cases, atypical cells suggesting UC variants appeared in the urine cytology, this study suggested that the preoperative cytological diagnosis of bladder cancer variants seems to be difficult.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03